Table 3.
KEGG enrichment analysis of potential core targets for MHD against LC
| Term | Gene count | P-value |
|---|---|---|
| hsa05200:Pathways in cancer | 49 | 7.22E-19 |
| hsa05169:Epstein-Barr virus infection | 40 | 1.42E-23 |
| hsa04151:PI3K-Akt signaling pathway | 32 | 7.35E-09 |
| hsa05203:Viral carcinogenesis | 31 | 5.50E-14 |
| hsa04110:Cell cycle | 29 | 3.03E-18 |
| hsa05202:Transcriptional misregulation in cancer | 29 | 1.42E-14 |
| hsa05168:Herpes simplex infection | 29 | 1.32E-13 |
| hsa05161:Hepatitis B | 28 | 2.43E-15 |
| hsa05034:Alcoholism | 26 | 1.87E-11 |
| hsa05166:HTLV-I infection | 25 | 2.00E-07 |
| hsa05215:Prostate cancer | 24 | 1.16E-16 |
| hsa04010:MAPK signaling pathway | 24 | 7.24E-07 |
| hsa04114:Oocyte meiosis | 23 | 2.00E-13 |
| hsa04120:Ubiquitin mediated proteolysis | 23 | 2.51E-11 |
| hsa05220:Chronic myeloid leukemia | 22 | 2.27E-16 |
| hsa04919:Thyroid hormone signaling pathway | 22 | 4.76E-12 |
| hsa04722:Neurotrophin signaling pathway | 22 | 1.34E-11 |
| hsa05160:Hepatitis C | 22 | 1.02E-10 |
| hsa05205:Proteoglycans in cancer | 22 | 1.81E-07 |
| hsa05206:MicroRNAs in cancer | 22 | 5.15E-05 |